Navigation Links
Selexis Now Offering Rapid-Development of Human Cell Line With FDA Approval Pedigree

New contract service offering rapid development of high performance HEK293 (human) production cell lines enabled by Selexis Genetic Elements(TM) and

Selexis SURE(TM) Cell Line Development program

GENEVA, July 16 /PRNewswire/ -- Selexis SA, a Swiss-based biotechnology company offering DNA based technologies and supportive services to enable significantly improved drug discovery, development, and cGMP production of biologics, announced today it has partnered with the National Research Counsel of Canada's Biological Research Institute (NRC-BRI) to offer the NRC-BRI HEK293 cell technologies for the contract development of high-performance stable human cell lines enabled by the Selexis Genetic Element(TM) and Selexis SURE Cell Line Development(SM) Services.

HEK293 cells are the most widely used HUMAN cell line in biotechnology industry and the ONLY human cell line used for the bioproduction of an FDA approved biopharmaceutical drug.

Xigrils(R), a recombinant form of human Activated Protein C, is marketed by Eli Lilly and Company for the treatment of severe sepsis. Xigrils(R) was approved by US-FDA in November of 2001 and is produced using HEK293 cells.

Dr. Igor Fisch, President and CEO of Selexis, commented:

"Partnering with the NCR-BRI to offer their well characterized human cell line is a perfect complement to our well developed and proven CHO platform, especially considering the fact that HEK293 cells have already been approved for the production of a recombinant protein drug."

"For over a decade Dr. Amine Kamen and his team of researchers at the BRI have done an outstanding job of developing their HEK293 program for large scale production purposes and now Selexis has the opportunity to make it more widely available with improved performance characteristics using our Selexis Genetic Element(TM) technology and our Selexis SURE Cell Line Development(SM) Services."

"This partnership will further reinforces Selexis' position as world leader of DNA-based technologies that significantly improve the long-term and stable expression of transgenes in a variety of eukaryotic host systems."

Dr. Pierre-Alain Girod, CSO of Selexis, commented:

"This combined program will be highly desirable to biotech companies needing the rapid development of a high performance cell line expressing proteins with human glycosylation patterns. This new platform will be a viable option to our CHO program for more difficult to express proteins."

About Selexis HEK293 Services:

Selexis is offering the global biotech market a proven avenue for the rapid development of high-performance HEK293 cell lines prepared under ICH guidelines and ready for cGMP manufacturing. Using the Selexis SURE Cell Line Development program, which is based on the use of the Selexis Genetic Element(TM) technologies, Selexis is now offering the development of stable clonal cell lines in as little as 12 weeks from transfection.

About Selexis:

Selexis is a privately held biotechnology company dedicated to the development of innovative technologies and expert services that enables significant improvements in the time, effort and costs required to develop and maintain high-performance mammalian cell lines used in the expression of pharmaceutically relevant proteins (i.e. targets, MABs, rProteins). The company's core intellectual property portfolio is based on the discovery and application of epigenetic DNA based elements that control the dynamic organization of chromatin within all mammalian cells. Application of the Selexis Genetic Elements(TM) using the SURE Cell Line Development process has enabled the rapid development of high performance cell lines for a number of pharmaceutically important programs.

Xigrils(R) is a registered trademark of Eli Lilly and Company.

SOURCE Selexis
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Exelixis Commences Public Offering of Common Stock
2. Eularis Announces New Corporate Name and Expanded Product Offerings
3. Healthcare Realty Trust Announces Public Offering of Common Stock
4. FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use
5. Volcano Corporation Announces Proposed Public Offering of Common Stock
6. Highlands Acquisition Corp. Completes Initial Public Offering
7. AKELA Pharma Inc. announces U.S. public offering and proposed listing
8. Society of Gynecologic Oncologists Provides Guidelines for Offering Genetic Risk Assessment to Women With a Personal or Family History of Breast, Ovarian, Uterine or Colorectal Cancer
9. Akron-Canton Airport offering flu shot clinic for 90 days
10. Uroplasty, Inc. Announces Filing of Registration Statement for Offering of Common Stock
11. Arena Pharmaceuticals Announces Public Offering of Common Stock
Post Your Comments:
(Date:11/26/2015)... ... , ... PRMA Plastic Surgery is updating their record books yet again with ... flap breast reconstruction surgery! , “What an accomplishment for the PRMA team, says ... it’s an honor to have served all of these women.” , PRMA is one ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel Film Studios brings Final ... ProTrailer: Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired designs, ... giving users limitless opportunities to stylize and create designs quickly and easily, all ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... Indosoft Inc., ... inclusion of an application server to improve system efficiency and reliability. , The new ... many of these standards, the system avoids locking itself into a specific piece of ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... Water For Empowerment ™ attracts volunteers together who want to combine talents ... women as key stakeholders in the process. The non-profit launched its first major ...
(Date:11/25/2015)... ... ... Finnleo, a leader in the traditional and far-infrared sauna industry, announced a sale ... , For traditional saunas, Finnleo is offering 20% off all Nordic Spruce ... only European Grade A Nordic White Spruce from sustainably grown trees. Because of the ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 Research ... of the "Advanced Wound Care Market by Type ... Ulcers), End User (In-Patient Facility, Out-Patient Facility), and Geography ... offering. --> --> ... the description, definition and forecast of the global advanced ...
(Date:11/26/2015)... November 26, 2015 ... adds "Global Repaglinide Industry ... Report on China Repaglinide Market, 2010-2019" ... data and information to its online ... . --> ...
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Italian therapeutic drug monitoring market, including emerging ...
Breaking Medicine Technology: